“A cost-effectiveness analysis of sotorasib as second-line treatment for patients with KRAS-G12C-mutated metastatic non-small cell lung cancer (mNSCLC) in Switzerland” (2025) Swiss Medical Weekly, 155(1), p. 3777. doi:10.57187/s.3777.